Associations between neurofilament light and imaging biomarkers of Alzheimer’s disease


  • Plasma neurofilament light (NfL), a marker of neuroaxonal injury, increases in response to amyloid-related neuronal injury in the preclinical stages of Alzheimer’s disease (AD) and tau-mediated neurodegeneration in the symptomatic course of the disease.

Why this matters

    Plasma NfL may be a beneficial biomarker of detecting early neuronal damage in neurodegenerative diseases, such as AD and monitoring treatment effects in drug trials.